nodes	percent_of_prediction	percent_of_DWPC	metapath
Quinidine barbiturate—Anaemia megaloblastic—Metformin—polycystic ovary syndrome	0.0602	0.121	CcSEcCtD
Quinidine barbiturate—Epigastric discomfort—Metformin—polycystic ovary syndrome	0.027	0.0544	CcSEcCtD
Quinidine barbiturate—Azotaemia—Metformin—polycystic ovary syndrome	0.0266	0.0537	CcSEcCtD
Quinidine barbiturate—Body temperature decreased—Metformin—polycystic ovary syndrome	0.0253	0.0511	CcSEcCtD
Quinidine barbiturate—Hypothermia—Metformin—polycystic ovary syndrome	0.0253	0.0511	CcSEcCtD
Quinidine barbiturate—Gastrointestinal symptom NOS—Metformin—polycystic ovary syndrome	0.0241	0.0487	CcSEcCtD
Quinidine barbiturate—KCNK1—adrenal cortex—polycystic ovary syndrome	0.0212	0.078	CbGeAlD
Quinidine barbiturate—GRIA2—embryo—polycystic ovary syndrome	0.021	0.0775	CbGeAlD
Quinidine barbiturate—KCNK1—endometrium—polycystic ovary syndrome	0.0189	0.0696	CbGeAlD
Quinidine barbiturate—CYP2D6—urine—polycystic ovary syndrome	0.0179	0.0659	CbGeAlD
Quinidine barbiturate—KCNK1—uterus—polycystic ovary syndrome	0.0174	0.0642	CbGeAlD
Quinidine barbiturate—KCNK1—pituitary gland—polycystic ovary syndrome	0.0171	0.063	CbGeAlD
Quinidine barbiturate—KCNK1—adipose tissue—polycystic ovary syndrome	0.0171	0.0628	CbGeAlD
Quinidine barbiturate—KCNK1—adrenal gland—polycystic ovary syndrome	0.0153	0.0563	CbGeAlD
Quinidine barbiturate—KCNK1—female gonad—polycystic ovary syndrome	0.0143	0.0525	CbGeAlD
Quinidine barbiturate—KCNK1—vagina—polycystic ovary syndrome	0.0142	0.0522	CbGeAlD
Quinidine barbiturate—Renal impairment—Metformin—polycystic ovary syndrome	0.0108	0.0218	CcSEcCtD
Quinidine barbiturate—GRIA2—endocrine gland—polycystic ovary syndrome	0.0108	0.0397	CbGeAlD
Quinidine barbiturate—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.0106	0.0213	CcSEcCtD
Quinidine barbiturate—Lethargy—Metformin—polycystic ovary syndrome	0.0105	0.0212	CcSEcCtD
Quinidine barbiturate—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.00951	0.0192	CcSEcCtD
Quinidine barbiturate—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00941	0.019	CcSEcCtD
Quinidine barbiturate—Breast disorder—Metformin—polycystic ovary syndrome	0.00931	0.0188	CcSEcCtD
Quinidine barbiturate—Quinine—CYP1A1—polycystic ovary syndrome	0.00925	0.439	CrCbGaD
Quinidine barbiturate—GABRA2—adipose tissue—polycystic ovary syndrome	0.00902	0.0332	CbGeAlD
Quinidine barbiturate—Angina pectoris—Metformin—polycystic ovary syndrome	0.00867	0.0175	CcSEcCtD
Quinidine barbiturate—SCN5A—vagina—polycystic ovary syndrome	0.00847	0.0312	CbGeAlD
Quinidine barbiturate—Neutropenia—Metformin—polycystic ovary syndrome	0.00832	0.0168	CcSEcCtD
Quinidine barbiturate—Quinidine—CYP1A1—polycystic ovary syndrome	0.00813	0.386	CrCbGaD
Quinidine barbiturate—GABRA2—adrenal gland—polycystic ovary syndrome	0.00809	0.0298	CbGeAlD
Quinidine barbiturate—Drowsiness—Metformin—polycystic ovary syndrome	0.00794	0.016	CcSEcCtD
Quinidine barbiturate—GABRA2—vagina—polycystic ovary syndrome	0.0075	0.0276	CbGeAlD
Quinidine barbiturate—Bradycardia—Metformin—polycystic ovary syndrome	0.00725	0.0146	CcSEcCtD
Quinidine barbiturate—Hepatitis—Metformin—polycystic ovary syndrome	0.00712	0.0144	CcSEcCtD
Quinidine barbiturate—KCNH2—endometrium—polycystic ovary syndrome	0.00695	0.0256	CbGeAlD
Quinidine barbiturate—CHRM2—endocrine gland—polycystic ovary syndrome	0.00674	0.0248	CbGeAlD
Quinidine barbiturate—Eye disorder—Metformin—polycystic ovary syndrome	0.00666	0.0134	CcSEcCtD
Quinidine barbiturate—Flushing—Metformin—polycystic ovary syndrome	0.00661	0.0133	CcSEcCtD
Quinidine barbiturate—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00661	0.0133	CcSEcCtD
Quinidine barbiturate—Immune system disorder—Metformin—polycystic ovary syndrome	0.00644	0.013	CcSEcCtD
Quinidine barbiturate—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00642	0.013	CcSEcCtD
Quinidine barbiturate—KCNH2—uterus—polycystic ovary syndrome	0.0064	0.0236	CbGeAlD
Quinidine barbiturate—Chills—Metformin—polycystic ovary syndrome	0.00639	0.0129	CcSEcCtD
Quinidine barbiturate—KCNH2—pituitary gland—polycystic ovary syndrome	0.00629	0.0231	CbGeAlD
Quinidine barbiturate—Erythema—Metformin—polycystic ovary syndrome	0.0062	0.0125	CcSEcCtD
Quinidine barbiturate—Malnutrition—Metformin—polycystic ovary syndrome	0.0062	0.0125	CcSEcCtD
Quinidine barbiturate—Vision blurred—Metformin—polycystic ovary syndrome	0.00585	0.0118	CcSEcCtD
Quinidine barbiturate—Tremor—Metformin—polycystic ovary syndrome	0.00581	0.0117	CcSEcCtD
Quinidine barbiturate—KCNH2—adrenal gland—polycystic ovary syndrome	0.00562	0.0207	CbGeAlD
Quinidine barbiturate—Syncope—Metformin—polycystic ovary syndrome	0.00556	0.0112	CcSEcCtD
Quinidine barbiturate—Palpitations—Metformin—polycystic ovary syndrome	0.00548	0.0111	CcSEcCtD
Quinidine barbiturate—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00545	0.011	CcSEcCtD
Quinidine barbiturate—Chest pain—Metformin—polycystic ovary syndrome	0.00528	0.0107	CcSEcCtD
Quinidine barbiturate—Myalgia—Metformin—polycystic ovary syndrome	0.00528	0.0107	CcSEcCtD
Quinidine barbiturate—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00524	0.0106	CcSEcCtD
Quinidine barbiturate—KCNH2—female gonad—polycystic ovary syndrome	0.00524	0.0193	CbGeAlD
Quinidine barbiturate—KCNH2—vagina—polycystic ovary syndrome	0.00521	0.0192	CbGeAlD
Quinidine barbiturate—Oedema—Metformin—polycystic ovary syndrome	0.00506	0.0102	CcSEcCtD
Quinidine barbiturate—Shock—Metformin—polycystic ovary syndrome	0.00498	0.01	CcSEcCtD
Quinidine barbiturate—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00496	0.01	CcSEcCtD
Quinidine barbiturate—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00496	0.01	CcSEcCtD
Quinidine barbiturate—Skin disorder—Metformin—polycystic ovary syndrome	0.00492	0.00992	CcSEcCtD
Quinidine barbiturate—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00489	0.00987	CcSEcCtD
Quinidine barbiturate—KCNH2—endocrine gland—polycystic ovary syndrome	0.00487	0.0179	CbGeAlD
Quinidine barbiturate—Anorexia—Metformin—polycystic ovary syndrome	0.00483	0.00973	CcSEcCtD
Quinidine barbiturate—Hypotension—Metformin—polycystic ovary syndrome	0.00473	0.00954	CcSEcCtD
Quinidine barbiturate—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00461	0.0093	CcSEcCtD
Quinidine barbiturate—Dyspnoea—Metformin—polycystic ovary syndrome	0.00451	0.0091	CcSEcCtD
Quinidine barbiturate—Somnolence—Metformin—polycystic ovary syndrome	0.0045	0.00908	CcSEcCtD
Quinidine barbiturate—Decreased appetite—Metformin—polycystic ovary syndrome	0.0044	0.00888	CcSEcCtD
Quinidine barbiturate—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00437	0.00882	CcSEcCtD
Quinidine barbiturate—Constipation—Metformin—polycystic ovary syndrome	0.00433	0.00873	CcSEcCtD
Quinidine barbiturate—Feeling abnormal—Metformin—polycystic ovary syndrome	0.00417	0.00842	CcSEcCtD
Quinidine barbiturate—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00414	0.00835	CcSEcCtD
Quinidine barbiturate—Urticaria—Metformin—polycystic ovary syndrome	0.00402	0.00811	CcSEcCtD
Quinidine barbiturate—Abdominal pain—Metformin—polycystic ovary syndrome	0.004	0.00807	CcSEcCtD
Quinidine barbiturate—Phenobarbital—CYP1A1—polycystic ovary syndrome	0.00368	0.175	CrCbGaD
Quinidine barbiturate—Asthenia—Metformin—polycystic ovary syndrome	0.00363	0.00733	CcSEcCtD
Quinidine barbiturate—Pruritus—Metformin—polycystic ovary syndrome	0.00358	0.00723	CcSEcCtD
Quinidine barbiturate—Diarrhoea—Metformin—polycystic ovary syndrome	0.00346	0.00699	CcSEcCtD
Quinidine barbiturate—Dizziness—Metformin—polycystic ovary syndrome	0.00335	0.00675	CcSEcCtD
Quinidine barbiturate—Vomiting—Metformin—polycystic ovary syndrome	0.00322	0.00649	CcSEcCtD
Quinidine barbiturate—CYP2D6—female gonad—polycystic ovary syndrome	0.00319	0.0118	CbGeAlD
Quinidine barbiturate—Rash—Metformin—polycystic ovary syndrome	0.00319	0.00644	CcSEcCtD
Quinidine barbiturate—Dermatitis—Metformin—polycystic ovary syndrome	0.00319	0.00643	CcSEcCtD
Quinidine barbiturate—Headache—Metformin—polycystic ovary syndrome	0.00317	0.0064	CcSEcCtD
Quinidine barbiturate—Nausea—Metformin—polycystic ovary syndrome	0.00301	0.00607	CcSEcCtD
Quinidine barbiturate—CYP2D6—endocrine gland—polycystic ovary syndrome	0.00297	0.0109	CbGeAlD
Quinidine barbiturate—CHRM2—GPCRs, Class A Rhodopsin-like—ADRA1D—polycystic ovary syndrome	0.000788	0.00373	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—TRPV6—polycystic ovary syndrome	0.000787	0.00372	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—AKR1C2—polycystic ovary syndrome	0.000775	0.00366	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP17A1—polycystic ovary syndrome	0.000769	0.00364	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCRs, Class A Rhodopsin-like—ADRA1B—polycystic ovary syndrome	0.000767	0.00362	CbGpPWpGaD
Quinidine barbiturate—GRIA2—BDNF signaling pathway—IRS2—polycystic ovary syndrome	0.000761	0.0036	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Oxidation by Cytochrome P450—CYP17A1—polycystic ovary syndrome	0.000759	0.00359	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Regulation of Actin Cytoskeleton—FGF18—polycystic ovary syndrome	0.000753	0.00356	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—PTGER3—polycystic ovary syndrome	0.000744	0.00352	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—LHCGR—polycystic ovary syndrome	0.000744	0.00352	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—DLG4—polycystic ovary syndrome	0.000742	0.00351	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmission across Chemical Synapses—CAMK2D—polycystic ovary syndrome	0.00074	0.0035	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—NR3C1—polycystic ovary syndrome	0.000716	0.00338	CbGpPWpGaD
Quinidine barbiturate—GRIA2—Neuronal System—DLG4—polycystic ovary syndrome	0.000712	0.00336	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—SCNN1A—polycystic ovary syndrome	0.000712	0.00336	CbGpPWpGaD
Quinidine barbiturate—KCNH2—Neuronal System—CAMK2D—polycystic ovary syndrome	0.000711	0.00336	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—PTAFR—polycystic ovary syndrome	0.000696	0.00329	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCRs, Other—ADRB2—polycystic ovary syndrome	0.000695	0.00329	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—NR3C1—polycystic ovary syndrome	0.000694	0.00328	CbGpPWpGaD
Quinidine barbiturate—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—polycystic ovary syndrome	0.000684	0.00323	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—NPB—polycystic ovary syndrome	0.000679	0.00321	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA1D—polycystic ovary syndrome	0.000675	0.00319	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—TRPV6—polycystic ovary syndrome	0.000671	0.00317	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Phase 1 - Functionalization of compounds—CYP11A1—polycystic ovary syndrome	0.000671	0.00317	CbGpPWpGaD
Quinidine barbiturate—GRIA2—BDNF signaling pathway—IRS1—polycystic ovary syndrome	0.000664	0.00314	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA1B—polycystic ovary syndrome	0.000657	0.00311	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—TH—polycystic ovary syndrome	0.000655	0.0031	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmission across Chemical Synapses—DLG4—polycystic ovary syndrome	0.000654	0.00309	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCRs, Class A Rhodopsin-like—FSHR—polycystic ovary syndrome	0.000635	0.003	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmission across Chemical Synapses—CAMK2D—polycystic ovary syndrome	0.000631	0.00298	CbGpPWpGaD
Quinidine barbiturate—KCNH2—Neuronal System—DLG4—polycystic ovary syndrome	0.000629	0.00297	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Calcium Regulation in the Cardiac Cell—CAMK2D—polycystic ovary syndrome	0.000625	0.00295	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Phase 1 - Functionalization of compounds—CYP17A1—polycystic ovary syndrome	0.000623	0.00295	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—polycystic ovary syndrome	0.000609	0.00288	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—SCNN1A—polycystic ovary syndrome	0.000607	0.00287	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—polycystic ovary syndrome	0.000601	0.00284	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—AR—polycystic ovary syndrome	0.000583	0.00276	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCRs, Class A Rhodopsin-like—ADRA1A—polycystic ovary syndrome	0.000581	0.00275	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Axon guidance—DLG4—polycystic ovary syndrome	0.000576	0.00272	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neuronal System—CAMK2D—polycystic ovary syndrome	0.000567	0.00268	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—LHCGR—polycystic ovary syndrome	0.000566	0.00268	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—PTGER3—polycystic ovary syndrome	0.000566	0.00268	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCRs, Class A Rhodopsin-like—ADRB3—polycystic ovary syndrome	0.000559	0.00264	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmission across Chemical Synapses—DLG4—polycystic ovary syndrome	0.000558	0.00264	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.000544	0.00257	CbGpPWpGaD
Quinidine barbiturate—CHRM2—G alpha (i) signalling events—MTNR1B—polycystic ovary syndrome	0.000532	0.00252	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.00053	0.0025	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.000514	0.00243	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—TH—polycystic ovary syndrome	0.000513	0.00243	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Neuronal System—DLG4—polycystic ovary syndrome	0.000501	0.00237	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—ADRA1B—polycystic ovary syndrome	0.0005	0.00236	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.000498	0.00235	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCRs, Class A Rhodopsin-like—MTNR1B—polycystic ovary syndrome	0.000494	0.00234	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.000493	0.00233	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.000491	0.00232	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.000484	0.00229	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neuronal System—CAMK2D—polycystic ovary syndrome	0.000483	0.00228	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.000479	0.00227	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.000474	0.00224	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—NR3C1—polycystic ovary syndrome	0.000472	0.00223	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Calcium Regulation in the Cardiac Cell—ADRB2—polycystic ovary syndrome	0.000469	0.00222	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.000463	0.00219	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—AR—polycystic ovary syndrome	0.000457	0.00216	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Calcium Regulation in the Cardiac Cell—GNAS—polycystic ovary syndrome	0.000435	0.00205	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.000431	0.00204	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Neuronal System—DLG4—polycystic ovary syndrome	0.000427	0.00202	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.000423	0.002	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.000415	0.00196	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—DLG4—polycystic ovary syndrome	0.000411	0.00194	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—ADIPOQ—polycystic ovary syndrome	0.000408	0.00193	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Biological oxidations—SULT2A1—polycystic ovary syndrome	0.000402	0.0019	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	0.000398	0.00188	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	0.000397	0.00187	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—SLC2A4—polycystic ovary syndrome	0.000385	0.00182	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.000383	0.00181	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.000379	0.00179	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—NR3C1—polycystic ovary syndrome	0.000369	0.00175	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	0.000366	0.00173	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.000365	0.00173	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—LHB—polycystic ovary syndrome	0.000361	0.0017	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Biological oxidations—CYP11A1—polycystic ovary syndrome	0.000356	0.00168	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.000352	0.00167	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	0.000351	0.00166	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—NPB—polycystic ovary syndrome	0.000348	0.00165	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.000347	0.00164	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—VEGFA—polycystic ovary syndrome	0.000344	0.00162	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00034	0.00161	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00034	0.00161	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—SCT—polycystic ovary syndrome	0.000338	0.0016	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—VEGFA—polycystic ovary syndrome	0.000333	0.00157	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	0.000332	0.00157	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Biological oxidations—CYP17A1—polycystic ovary syndrome	0.000331	0.00157	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	0.000327	0.00154	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.000322	0.00152	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.00032	0.00151	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.00032	0.00151	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.000315	0.00149	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.000313	0.00148	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—NCOR1—polycystic ovary syndrome	0.000308	0.00145	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.000302	0.00143	CbGpPWpGaD
Quinidine barbiturate—CHRM2—G alpha (i) signalling events—GNAS—polycystic ovary syndrome	0.000302	0.00143	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.000299	0.00142	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	0.000297	0.0014	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	0.000296	0.0014	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.000291	0.00137	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.000291	0.00137	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.000291	0.00137	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.000283	0.00134	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	0.000276	0.00131	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.000272	0.00129	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.000264	0.00125	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Biological oxidations—CYP19A1—polycystic ovary syndrome	0.000262	0.00124	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.000259	0.00122	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	0.000258	0.00122	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.000257	0.00122	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.000257	0.00121	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	0.000253	0.0012	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—LEP—polycystic ovary syndrome	0.000253	0.0012	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	0.000253	0.00119	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.000238	0.00113	CbGpPWpGaD
Quinidine barbiturate—SCN5A—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	0.000238	0.00112	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	0.000235	0.00111	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—FLT4—polycystic ovary syndrome	0.000235	0.00111	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.000234	0.00111	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.000234	0.0011	CbGpPWpGaD
Quinidine barbiturate—KCNH2—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	0.00023	0.00109	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—VEGFA—polycystic ovary syndrome	0.000226	0.00107	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—PPARG—polycystic ovary syndrome	0.00022	0.00104	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—INS—polycystic ovary syndrome	0.000216	0.00102	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	0.000215	0.00102	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.000214	0.00101	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.000213	0.00101	CbGpPWpGaD
Quinidine barbiturate—GABRA2—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	0.000212	0.001	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Biological oxidations—CYP1A1—polycystic ovary syndrome	0.000211	0.000999	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—AKT2—polycystic ovary syndrome	0.000209	0.000988	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	0.000208	0.000985	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.000206	0.000975	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—NPB—polycystic ovary syndrome	0.000206	0.000972	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.000204	0.000963	CbGpPWpGaD
Quinidine barbiturate—CHRM2—G alpha (i) signalling events—POMC—polycystic ovary syndrome	0.000203	0.000961	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.000199	0.000942	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.000197	0.000932	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.000195	0.00092	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Axon guidance—VEGFA—polycystic ovary syndrome	0.000191	0.000905	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.000191	0.000903	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.000187	0.000885	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.000186	0.000879	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—NMNAT3—polycystic ovary syndrome	0.000186	0.000878	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—LHB—polycystic ovary syndrome	0.000185	0.000875	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.000183	0.000864	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.000182	0.000861	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.000181	0.000855	CbGpPWpGaD
Quinidine barbiturate—GABRA1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	0.000181	0.000854	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—VEGFA—polycystic ovary syndrome	0.000177	0.000838	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—SCT—polycystic ovary syndrome	0.000173	0.00082	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000172	0.000812	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000172	0.000812	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—LPCAT2—polycystic ovary syndrome	0.00017	0.000803	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—SUOX—polycystic ovary syndrome	0.00017	0.000803	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.000165	0.000782	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.000162	0.000764	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000161	0.000759	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—ISYNA1—polycystic ovary syndrome	0.000158	0.000747	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Biological oxidations—POMC—polycystic ovary syndrome	0.000157	0.000745	CbGpPWpGaD
Quinidine barbiturate—GABRA1—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	0.000157	0.00074	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000156	0.000737	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000152	0.000717	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000148	0.000699	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000138	0.000652	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—VEGFA—polycystic ovary syndrome	0.000137	0.000646	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000135	0.000636	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—TEAD2—polycystic ovary syndrome	0.000134	0.000635	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—AKR1C2—polycystic ovary syndrome	0.000134	0.000635	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Axon guidance—IL6—polycystic ovary syndrome	0.000132	0.000626	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000126	0.000594	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000123	0.000582	CbGpPWpGaD
Quinidine barbiturate—CHRM2—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	0.000123	0.000579	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000122	0.000578	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000118	0.000559	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000115	0.000543	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	0.000113	0.000532	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—FST—polycystic ovary syndrome	0.000112	0.000529	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000111	0.000526	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000111	0.000523	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—LHB—polycystic ovary syndrome	0.000109	0.000517	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000107	0.000505	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	0.000107	0.000504	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000103	0.000489	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000103	0.000488	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—SCT—polycystic ovary syndrome	0.000102	0.000484	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	0.000102	0.000481	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000101	0.000478	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	9.77e-05	0.000462	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—FGF18—polycystic ovary syndrome	9.6e-05	0.000454	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—RBP4—polycystic ovary syndrome	9.52e-05	0.00045	CbGpPWpGaD
Quinidine barbiturate—SCN5A—Developmental Biology—IL6—polycystic ovary syndrome	9.45e-05	0.000447	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—GNAS—polycystic ovary syndrome	9.38e-05	0.000443	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	9.07e-05	0.000429	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—YAP1—polycystic ovary syndrome	8.89e-05	0.00042	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—GAB1—polycystic ovary syndrome	8.77e-05	0.000415	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	8.66e-05	0.000409	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—INSR—polycystic ovary syndrome	8.38e-05	0.000396	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	7.97e-05	0.000377	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	7.89e-05	0.000373	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	7.84e-05	0.000371	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—PGR—polycystic ovary syndrome	7.76e-05	0.000367	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	7.72e-05	0.000365	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	7.47e-05	0.000353	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—PLAT—polycystic ovary syndrome	7.22e-05	0.000341	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—GHRL—polycystic ovary syndrome	7.22e-05	0.000341	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—POMC—polycystic ovary syndrome	6.95e-05	0.000329	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—ATF1—polycystic ovary syndrome	6.89e-05	0.000325	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	6.88e-05	0.000325	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	6.71e-05	0.000317	CbGpPWpGaD
Quinidine barbiturate—CHRM2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	6.68e-05	0.000316	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	6.66e-05	0.000315	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	6.42e-05	0.000303	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—NGFR—polycystic ovary syndrome	6.35e-05	0.0003	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—POMC—polycystic ovary syndrome	6.31e-05	0.000298	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—PRL—polycystic ovary syndrome	6.3e-05	0.000298	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	6.17e-05	0.000292	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	6.09e-05	0.000288	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—AKT2—polycystic ovary syndrome	6.07e-05	0.000287	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—ADRB2—polycystic ovary syndrome	5.97e-05	0.000282	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	5.75e-05	0.000272	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	5.66e-05	0.000268	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—GNAS—polycystic ovary syndrome	5.54e-05	0.000262	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.28e-05	0.000249	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—NRG1—polycystic ovary syndrome	5.18e-05	0.000245	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—TH—polycystic ovary syndrome	4.9e-05	0.000232	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	4.77e-05	0.000225	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	4.48e-05	0.000212	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—IRS2—polycystic ovary syndrome	4.44e-05	0.00021	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—LEP—polycystic ovary syndrome	4.34e-05	0.000205	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	4e-05	0.000189	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—IRS1—polycystic ovary syndrome	3.87e-05	0.000183	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	3.81e-05	0.00018	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—POMC—polycystic ovary syndrome	3.73e-05	0.000176	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—INS—polycystic ovary syndrome	3.71e-05	0.000175	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	3.61e-05	0.000171	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—IGF1—polycystic ovary syndrome	3.59e-05	0.00017	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—AKT2—polycystic ovary syndrome	3.59e-05	0.000169	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.41e-05	0.000161	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	3.37e-05	0.000159	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling by GPCR—IL6—polycystic ovary syndrome	2.74e-05	0.00013	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	2.73e-05	0.000129	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	2.69e-05	0.000127	CbGpPWpGaD
Quinidine barbiturate—CYP2D6—Metabolism—INS—polycystic ovary syndrome	2.68e-05	0.000127	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.34e-05	0.000111	CbGpPWpGaD
Quinidine barbiturate—CHRM2—Signaling Pathways—IL6—polycystic ovary syndrome	1.62e-05	7.66e-05	CbGpPWpGaD
